Research Divisions

Medical Oncology

Group LeaderLocation and ContactMembersHistory of the GroupLines of ResearchNotable PublicationsProjectsPhD ThesesClinical TrialsPatents and TrademarksNews
Dr Emilio Esteban González ISPA grupos de investigación CROS
Dr Emilio Esteban González

I was born in Mieres, Asturias, on 12 January 1959. I began my university career in the Faculty of Medicine at the Universidad de Oviedo, where I studied between 1976 and 1982. In October 1982, I was awarded my degree in Medicine with a classification of ‘Notable’ (2:1, UK; B, US). In the same year, I entered the public exam for the Spanish Medical Residency Programme (MIR) 1983 and obtained a post, but had to turn it down when I was called up for military service. I entered the Medical Residency Programme exam again for 1984 and gained a post in medical oncology at the Hospital General de Asturias, where I began my specialist training in June 1984, completing it in December 1987.

From January to June 1988, I worked as an interim consultant in the same department of the Hospital General de Asturias. I then completed the public exam for a Consultant post in the Medical Oncology Department of the Hospital General de Asturias (Resolution of 8 February 1988) in June 1988 and obtained the position, starting work as an oncologist in the Medical Oncology Department of the Hospital Universitario Central de Asturias (HUCA) on 14 July 1988, where my duties involved patient care, research and teaching work.

On 9 May 2011, I was appointed Head of the Medical Oncology Department at HUCA. I obtained my PhD in Medicine and Surgery from the Universidad de Oviedo in April 1994, achieving the classification of ‘cum laude’.

I have completed postings in prestigious hospitals such as the Hospital Doce de Octubre in Madrid and the Hospital Marqués de Valdecilla in Santander, where I developed my knowledge of high-dose chemotherapy, as well as autologous and heterologous marrow transplants.

Through another posting, at Hospital MD Anderson in the US, I expanded my knowledge of cutting-edge treatment for non-small cell lung cancer in the Head, Neck and Lung department with Doctor Fossella.

I have been a member of the Sociedad Española de Oncología Médica (Spanish Medical Oncology Society) since May 1990 and a member of the European and American Medical Oncology societies since 1995 and 1999, respectively.

I was an Associate Lecturer at the Faculty of Medicine in Oviedo until October 2009, delivering classes on the Oncology module, and have been a Tenured Lecturer since September 2016. I am a reviewer for the following international journals: British Journal of Cancer, Biomed, Drugs, Expert Reviews, Journal of Thoracic Oncology, Oncology, Advances in Therapy, Clinical and Translational Oncology, Cancer Treatment Review, Therapeutic Advances in Medical Oncology and World Journal of Surgical Oncology (WJSO).

I was a member of the editorial board for the Oncología journal in 2005 and have been on the editorial boards of the Journal of Cancerology since 2014 and the Journal of Thoracic Disease (JTD) since October 2016.

I have been director of the Medical Oncology Laboratory of the Instituto Universitario de Oncología del Principado de Asturias (IUOPA) since 28 June 2007.

Hospital Universitario Central de Asturias

Avenida Roma S/N, 33011 Oviedo, Spain.

Name Organisation Activity Euraxess classification
Castillo Trujillo, Alfredo SESPA Research/Clinical/Teaching R2
Esteban González, Emilio Universidad de Oviedo/SESPA Research/Clinical/Teaching R3
Fernández Arrojo, Sara SESPA Research/Clinical/Teaching R2
Fernández Fernández, José Luis SESPA Research/Clinical/Teaching R2
Fernández Pérez, Yolanda SESPA Research/Clinical/Teaching R2
García Llano, Juan Luis SESPA Research/Clinical/Teaching R2
Izquierdo Manuel, Marta Esther SESPA Research/Clinical/Teaching R2
Jiménez Fonseca, Paula SESPA Research/Clinical/Teaching R2
Muñiz Castrillo, María SESPA Research/Clinical/Teaching R2
Muñiz García, Isabel SESPA Research/Clinical/Teaching R2
Palacio Vázquez, Isabel SESPA Research/Clinical/Teaching R2
Revuelta Rodríguez, Alfonso SESPA Research/Clinical R2
Solís Hernández, Pilar SESPA Research/Clinical/Teaching R2
Villanueva Palicio, Noemí SESPA Research/Clinical/Teaching R2

Medical Oncology ISPA

After the Medical Oncology department was created in the 1970s, its engagement with research began through partnerships with international research networks such as the European Organisation for Research and Treatment of Cancer (EORTC), followed by collaboration with the university through the IUOPA Medical Oncology Laboratory. The clinical members of the research group have extensive experience in patient care and have spent years prescribing and applying the necessary cytotoxic and cytostatic treatments to patients affected by malignant tumours of various origins. The group’s research, with direct applications in the Spanish National Health System, has contributed to improvements and changes in protocols and clinical guidelines on care practice. It has also generated a large number of international publications in peer-reviewed journals.

In the laboratory, research initially focused on pharmacokinetics (in 2002), with the aim of identifying kinetic interactions between the antitumour drugs included in combined therapies, as well as their pharmacodynamic effect. Given that all of these studies showed a large degree of interindividual variability, research began in 2006 on pharmogenetic variables that could help explain this and facilitate the personalisation of systemic oncological treatments. The group has also collaborated with other IUOPA research groups, the Analytical Chemistry section of the Universidad de Oviedo and the University of Stanford. It also works with national and international research networks on studies that analyse prognostic and predictive variables regarding the tissue and serum response to anti-angiogenic treatments in patients with solid tumours.

Since 2009, the research team has been involved in 73 clinical trials, sponsored by the pharmaceutical industry as well as by national and international research networks. Some of the most significant of the trials sponsored by the IUOPA Medical Oncology Laboratory include:

Translational Research

1 – A Study of Pemetrexed plus Oral Vinorelbine in Non-squamous Non-small Cell Lung Cancer: a Phase I/II Clinical Trial.

  • Sponsored by: Lilly
  • Total:
  • Period: 2009-2014
  • Research Team: Emilio Esteban (PI), Marta Sierra, Raquel Losa, Noemí Villanueva, Carlos Álvarez, Iriana Zambrano.

2 – A Phase I/II Pharmacokinetics and Pharmacogenetics Study: Implications for Optimising the Use of Intravenous Pemetrexed Combined with Oral Vinorelbine in Advanced Non-small Cell Lung Cancer Patients.

  • Sponsored by: Instituto de Salud Carlos III. File No EC08/00008.
  • Period: 2009-2012
  • Research Team: Emilio Esteban (PI), Marta Sierra, Raquel Losa, Joaquín Fra, Pilar Blay, Yolanda Fernández, Angel J Lacave, José María Viéitez, Noemí Villanueva, Angeles Carreira, Dolores Lorenzo, Mónica Camblor.

Medium-Term Scientific Objectives

Our main objective is to develop increasingly efficient pharmacological treatments with lower toxicity for solid tumours in adults. For this purpose, we will continue to participate in phase I, II, III and IV clinical trials sponsored by the pharmaceutical industry and national and international research networks. We will also continue trying to identify – in peripheral blood and fluids such as urine and saliva (easily accessible biological matrices) – prognostic and predictive markers of response to and/or toxicity of chemotherapy agents, tyrosine kinase inhibitors and immune modulators. We search for these markers through pharmacokinetic and pharmacogenetic studies, which enable patients to be stratified and thereby receive antitumour treatments that suit their characteristics, the intention being to optimise therapeutic performance and reduce toxicity.

Pharmacological treatment of solid human tumours.

Pharmacokinetics and pharmacogenetics of antitumour therapies.

  1. AUTHORS: J. Garcia-Donas, L. J. Leandro-García, A. González del Alba, M. Morente, I. Alemany, E. Esteban, J. A. Arranz, M. A. Climent, E. Gallardo, and C. Rodríguez-Antona
    TITLE: Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
    Ann Oncol (2013) doi: 10.1093/annonc/mdt219First published online: June 20, 2013.
  2. AUTHORS: Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J
    TITLE: Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
    TUGAMO GROUP. Br J Cancer. 2013 Jun 25. doi: 10.1038/bjc.2013.272.
  3. AUTHORS: de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Alvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, Del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J.
    TITLE: Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
    Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270.
  4. AUTHORS: Carlos Alvarez-Fernández- Quionia Perez-Arnillas, Lucrecia Ruiz-Echevarria, David Rodriguez-Rubi, Luisa Sanchez-Lorenzo, Walter Li-Torres, Marta Izquierdo-Manuel, Jose P. Berros, María Luque-Cabal, Paula Jimenez-Fonseca, Noemi Villanueva-Palicio, Emilio Esteban-González
    TITLE: Reduced folate carrier (RFC) as predictive marker for response to pemetrexed in advanced non-small-cell lung cancer (NSCLC).
    Investigational New Drugs; DOI 10.1007/s10637-013-9992-1
  5. AUTHORS: Thomas E. Hutson, Bernard Escudier, Emilio Esteban, et al.
    TITLE: Randomized phase III trial of temsirolimus versus sorafenib as second line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Journal Clinic of Oncology. Doi: 10.1200/JCO.2013.50.5305
  6. AUTHORS: Robert J Motzer, Camillo Porta, Nicholas J Vogelzang, Cora N Sternberg, Cezary Szczylik, Jakub Zolnierek, Christian Kollmannsberger, Sun Young Rha, Georg A Bjarnason, Bohuslav Melichar, Ugo De Giorgi, Viktor Grünwald, Ian D Davis, Jae-Lyun Lee, Emilio Esteban, Gladys Urbanowitz, Can Cai, Matthew Squires, Mahtab Marker, Michael M Shi, Bernard Escudier
    TITLE: Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
    Lancet of Oncology. Published online February 17, 2014
  7. AUTHORS: Renal Cell Carcinoma. New Strategies for Advanced Renal Cell Carcinoma. Emilio Esteban González, Noemi Villanueva Palicio, Carlos Álvarez Fernández, Luisa Sánchez Lorenzo, Pilar Solis Hernández, Department of Medical Oncology Hospital Universitario Central de Asturias, Oviedo, Spain. 2015. pp.249-264
    TITLE: Cancer Etiology, Diagnosis and Treatments
    Binding: Hardcover. ISBN: 978-1-63482-495-8
  8. AUTHORS: Luis León, Luis Miguel Antón-Aparicio, Emilio Esteban-González, Martin Lázaro-Quintela, and Sergio Vázquez Éstevez (377)
    TITLE: Renal Cell Carcinoma. Molecular Targets and Clinical Applications. Chapter 18 Side Effects of Targeted Therapy
    Third Edition. ISBN 978-1-4939-1621-4 ISBN 978-1-4939-1622-1 (eBook) DOI 10.1007/978-1-4939-1622-1 Springer New York Heidelberg Dordrecht London Library of Congress Control Number: 2014955159.
  9. AUTHORS: E. Esteban a, M. Majem b, M. Martinez Aguillo c, N. Martinez Banaclocha d, M. Do ́ mine e, L. Go ́ mez Aldaravi f, O. Juan g, R. Cajal h, M.C. Gonzalez Arenas h, M. Provencio i
    TITLE: Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study.
    G ModelCANEP-819; No. of Pages 7. Cancer Epidemiology xxx (2015) xxx–xxxCancer Epidemiology The International Journal of Cancer Epidemiology, Detection, and Preventionjournal
  10. AUTHORS: Xu CF, Johnson T, Garcia-Donas J, Choueiri TK, Sternberg CN, Davis ID, Bing N, Deen KC, Xue Z, McCann L, Esteban E, Whittaker JC, Spraggs CF, Rodríguez-Antona C, Pandite LN, Motzer RJ.
    TITLE: IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
    Br J Cancer. 2015 Mar 31;112(7):1190-8. doi: 10.1038/bjc.2015.64. PMID: 25695485 (PubMed – indexed for MEDLINE]).
  11. AUTHORS: Arriola E, Reguart N, Artal A, Cobo M, García-Campelo R, Esteban E, Rodríguez MC, García-Muret MP.
    TITLE: Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.
    Future Oncol. 2015;11(2):267-77. doi: 10.2217/fon.14.214. Epub 2014 Sep 19. Review. PMID: 25236437 (PubMed – indexed for MEDLINE)
  12. AUTHORS: Javier Puente, Xavier García del Muro, Álvaro Pinto, Nuria Láinez, Emilio Esteban, José Ángel Arranz, Enrique Gallardo, María José Méndez, Pablo Maroto, Enrique Grande, Cristina Suárez
    TITLE: Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
    Targ Oncol DOI 10.1007/s11523-015-0408-3
  13. AUTHORS: Nuria Lainez, Jesús García-Donas, Emilio Esteban, Javier Puente, et al.
    TITLE: Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
    BMC Cancer (2016) 16:135.
  14. AUTHORS: D. Calvo Temprano ; E, Esteban; P.Jimenez Fonseca; B. Fernández – Mariño
    TITLE: CT scan prior to radiotherapy in unresectable, locally advanced, non-small cell carcinoma of the lung: is it always necessary?
    Clinical and Translational Oncology Clinical and Translational Oncology. ISSN: 1699-048X (Print) 1699-3055 (Online). april 2015, 1-6.
  15. AUTHORS: F Vansteenkiste, Byoung Chul Cho, Tonu Vanakesa, Tommaso De Pas, Marcin Zielinski, Moon Soo Kim, Jacek Jassem, Masahiro Yoshimura, Jubrail Dahabreh, Haruhiku Nakayama, Libor Havel, Haruhiko Kondo, Tetsuya Mitsudomi, Konstantinos Zarogoulidis, Oleg A Gladkov, Katalin Udud, Hirohito Tada, Hans Hoffman, Anders Bugge, Paul Taylor, Emilio Esteban González
    TITLE: Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
    Lancet Oncol 2016
    Published Online April 27, 2016 S1470-2045(16)00099-1
    See Online/Comment S1470-2045(16)30031-6
  16. AUTHORS: Julio Lambea, Urbano Anido, Olatz Etxániz, Luis Flores, Álvaro Montesa, Juan Manuel Sepúlveda, Emilio Esteban
    TITLE: The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma
    Curr Oncol Rep (2016) 18:66 DOI 10.1007/s11912-016-0553-6
  17. AUTHORS: Manuel Dómine Gomez, Nieves Dıaz Fernández, Blanca Cantos Sanchez de Ibarguen, Luis Zugazabeitia Olabarŕıa, Joaquina Martinez Lozano, Raul Poza de Celis, Rafael Trujillo Vílchez, Ignacio Pelaez FernÁndez, Jaume Capdevila Castillón, Susana Traseira Lugilde, Emilio Esteban González
    TITLE: Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting
    Adv Ther. 2017 Jan;34(1):136-147
  18. AUTHORS: Miguel F. Sanmamed, E. Esteban, E. Uriol, R. Zarate, M. Capelan, C. Muriel, G. Crespo, J. P. Berros, P. Pardo‐Coto, Q. Perez, C. Alvarez‐Fernández, P. Jiménez Fonseca, M. Luque and A. Astudillo
    TITLE: Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours.
    J Transl Med (2017) 15:62 DOI 10.1186/s12967-017-1162-3
  19. AUTHORS: Aránzazu González del Alba, José Ángel Arranz, Javier Puente, María José Méndez-Vidal, Enrique Gallardo, Enrique Grande, Begoña Pérez-Valderrama, Enrique González-Billalabeitia, Martín Lázaro-Quintela, Álvaro Pinto, Nuria Lainez, Josep M. Piulats, Emilio Esteban, José Pablo Maroto Rey, Jorge A. García, Cristina Suárez
    TITLE: Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
    Oncology Hematology 2017: 113; 171-190
  20. AUTHORS: Javier Puente, Nuria Laínez, Marta Dueñas, María José Méndez-Vidal, Emilio Esteban, Daniel Castellano, Mónica Martinez-Fernández, Laura Basterretxea, María José Juan-Fita, Luis Antón, Luis León, Julio Lambea, Begoña Pérez- Valderrama, Sergio Vázquez, Cristina Suarez, Xavier Garcia del Muro, Enrique Gallardo, José Pablo Maroto, Luz Samaniego, Beatriz Suárez-Paniagua, Julián Sanz, Jesús Paramio, SOGUG (Spanish Oncology Genitourinary Group)
    TITLE: Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
    Oncotarget. 2017; 8:30410-30421. doi: 10.18632/oncotarget.16494
  21. AUTHORS: P Maroto, E Esteban, E Fernández Parra, MJ Mendez-Vidal, M Domenech, B Pérez-Valderrama, V Calderero, JL Pérez-Gracia, E Grande, F Algaba
    TITLE: HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma.
    OncoTargets and Therapy 2017:10 4635–4643
  22. AUTHORS: Enrique Gonzáez-Billalabeitia, Juan Manuel Sepúlveda, Pablo Maroto, Jorge Aparicio, José Ángel Arranz, Emilio Esteban, Regina Gironés, Marta López-Brea, María José Mendez-Vidal, Álvaro Pinto, Javier Sastre, Diego Soto de Prado, Josefa Terrasa, Sergio Vázquez, Thomas Powles, Jörg Beyer, Daniel Castellano, Xavier García del Muro, on behalf of the Spanish Germ Cell Cancer Group and the Spanish Oncology Genitourinary Group
    TITLE: Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer.
    EUROPEAN UROLOGY FOCUS 3 (2017) 280–286
  23. AUTHORS: Daniel Castellanos, Jose Pablo Maroto, Enrique Grande, Victoria Bolos, Julia Linares, Emilio Esteban
    TITLE: Experience with sunitinib in metastatic renal cell carcinoma patients: Pooled análisis from 3 Spanish observational prospective Studies.
    Expert Opinion On drug Safety. Agosto 2017
  24. AUTHORS: L. Gandhi, D. Rodríguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y.-S. Cheng, H.G. Bischoff, N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J.E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M.C. Pietanza, and M.C. Garassino for the KEYNOTE-189 Investigators
    TITLE: Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer.
    DOI:10.1056/NEJMoa1801005. New England Journal of Medicine 2018
Principal Investigator Title Funding Body Amount Duration Number of Researchers
Emilio Esteban González A study of pemetrexed plus oral vinorelbine in non-squamous non-small cell lung cancer: a phase I/II clinical trial Lilly €150,000 12
A phase I/II pharmacokinetics and pharmacogenetics study: implications for optimising the use of intravenous pemetrexed combined with oral vinorelbine in advanced non-small cell lung cancer patients Instituto de Salud Carlos III. File No EC08/00008 €136,730 2009 – 2012 12
Emilio Esteban SOGUG-ANG-2013-01. An observational, prospective, multicentre study to identify prognostic and predictive biomarkers of response to approved angiogenic drugs in the first line treatment of locally advanced, metastatic renal cell carcinomas. SOGUG
PhD Student Title Year
Pablo Pardo Coto Analysis of the P38 MAPK pathway and its prognostic role in limited-stage non-small cell lung cancer 2013 – 2014
Lucía González Llorente A study of the influence of tumour stromal fibroblasts in the behaviour of mammary carcinomas 2013 – 2014
Jose Pablo Berros Fombella Clinical experience with tyrosine kinase inhibitors in non-small cell lung cancer 2012 – 2013
David Calvo Temprano The role of computed tomography in therapeutic decisions regarding clinical practice and simple radiography 2011 – 2012
Carolina Muriel López Prognostic and predictive factors regarding response to specific anti-angiogenic treatment in patients with advanced kidney cancer 2010 – 2011
Miguel Fernández de Sanmame Gutierrez Prognostic factors in stage I testicular germ-cell tumours 2010 – 2011

Dr Emilio Esteban González

  1. A Randomised , Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS) EORTC-1416-LCG/ETOP/MK-3475-091-00. Start Date 04 March 2016.
  2. A Phase III, Randomised, Open-Label, Multi-Centre, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC) ABI-007-NSCL-003. Start Date 07 March 2016.
  3. A Randomised, Double-Blind, Phase III Study of Platinum + Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189) MK 3475-189. Start Date 09 March 2016.
  4. A Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received One or Two Prior Lines of Systemic Therapy for Advanced/Metastatic Disease. CINC280A2201. Start Date 18 April 2016.
  5. A Study to Determine the Concordance of Key Actionable Genomic Alterations as Assessed in Tumour Tissue and Plasma From Patients With Non Small Cell Lung Carcinoma (NSCLC) 14-009 Start Date 24 October 2016.
  6. A Phase 3 Multicentre Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer AP26113-13-301. Start Date 12 December 2016.
  7. “A Postauthorisation , Observational, Prospective Study to Evaluate Disease Progression Patterns in Patients with EGFR Activating Mutation Positive Advanced Non Small Cell Lung Cancer (NSCLC) in First-Line Treatment with Erlotinib (Tarceva®).” Protocol Code: ROC-ERL-2012-01. Sponsor: Roche Farma, S.A. ASPET.
  8. “Randomised Study of Customised Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Stages II-IIIA Non-Small-Cell Lung Cancer Patients” Protocol Code: GECP-SCAT. Sponsor: Grupo Español de Cáncer de Pulmón. SCAT.
  9. “A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung”. Protocol Code: 1200.123. Sponsor: Boehringer Ingelheim. LUX-LANG.
  10. “A Phase III Multicentre, Randomised Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer”. Protocol Code: CLDK378A2301. Sponsor: Novartis. CLDK.
  11. “An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutation(s)”. Protocol Code: 1200.55. Sponsor: Boehringer Ingelheim.
  12. “A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumours”. Protocol Code: CINC280X2102. Sponsor: Novartis.
  13. “Open Label, Multinational, Multicentre, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)”. Protocol Code: D5160C00022. Sponsor: AstraZeneca. ASTRIS.
  1. Observational, Prospective Study to Assess Bone Biomarkers for TKI Response in RCC Patients With Bone Metastasis and the Impact of TKI on HRQoL in These Patients as Well as Comparing the Sensitivity and Specificity of Whole Body MRI vs. Bone Scintigraphy in the Assessment and Detection of Bone Metastases. SOG-ANG-2014-01- Metheos. Start Date 15 December 2016.
  2. Multicentric and Prospective Epidemiological Study to Identify Prognosis and Predictive Biomarkers of Response to Angiogenic Drugs Approved in First Line of Treatment for Advanced or Metastatic Renal Cell Carcinoma. Protocol Code: SOG-ANG-2013-01. Sponsor: SOGUG – Spanish Cooperative Group in GU Tumours.
  3. Adjuvant Axitinib Treatment of Renal Cancer: A Randomised Double-blind Phase 3 Study of Adjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC. Protocol Code: AP311736. Sponsor: Pfizer. ATLAS.
  4. “A Randomised, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects with Localised or Locally Advanced RCC Following Nephrectomy” Protocol Code: VEG113387 Sponsor: GlaxoSmithKline S.A (GSK). PROTEC.
  5. “A Biological Study to Determine Possible Predictive Factors of Response to Pazopanib in Monotherapy and to Determine Efficiency and Safety in Second-line of Treatment in Patients With Carcinoma of Advanced Renal Cells That Have Progressed or Have Not Tolerated the First Line of Treatment With Tyrosine Kinase Inhibitor” Protocol Code: APRO02-2011. Sponsor: Associació per a la Recerca Oncològica (Cancer Research Association, APRO).
  6. “Randomised Phase II Study to Explore Efficacy and Feasibility of Upfront Rotations Between Sunitinib and Everolimus Versus Sequential Treatment of 1st Line Sunitinib and 2nd Line Everolimus Until Progression in Patients with Metastatic Clear Cell Renal Cancer” Protocol Code: CRAD001LIC34T. Sponsor: APRO SUNRISES.
  7. “A Phase 3, Randomised, Controlled Study of Cabozantinib (XL184) Versus Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy”. Protocol Code: XL184-308 (METEOR). Sponsor: Exelixis INC.
  8. “Sorafenib Long Term Extension Program (STEP)”. Protocol Code: BAY43-9006-12311. Sponsor: Bayer HealthCare AG. STEP.
  9. “A Phase 3, Randomised, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma”. Protocol Code: CA209-214. Sponsor: Bristol Myers-Squibb Company.
  1. “A Phase 3, Randomised, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100”. Protocol Code: XL184-307 (COMET-1). Sponsor: Exelixis Inc. COMET.
  2. Abiraterone Acetate Maintenance in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer (mCRPC). Protocol Code: ABIDO-SOGUG. Sponsor: Spanish Oncology Genitourinary Group – SOGUG. ABIDO.
  3. A Phase III Randomised, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer (CRPC). Protocol Code: BAY 88-8223 / 15396. Sponsor: Bayer HealthCare. ERA.
  4. “A Phase 3 Randomised, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer”. Protocol Code: 10TASQ10. Sponsor: Active Biotech AB.

“A Phase III, Open-label, Multicentre, Randomised Study of MPDL3280A (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients with PD-L1-selected, High Risk Muscle Invasive Bladder Cancer After Cystectomy”. Protocol Code: WO 29636. Sponsor: Roche.

Dr Paula Jiménez Fonseca

  1. “Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumour (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib” RESUNET (GETNE-2016-01).
  2. Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days. 8-79-52030-326 (CLARINET FORTE).
  3. Multicentre 3-arm Trial to Evaluate the Efficacy and Safety of Pasireotide LAR or Everolimus Alone or in Combination in Patients With Well Differentiated Neuroendocrine Carcinoma of the Lung and Thymus. Protocol Code: CSOM230DIC03. Sponsor: Novartis. LUNA.
  4. “A Phase II Randomised Double -blind Study of Santostatin LAR in Combination with Axitinib Versus Placebo in Patients with Advanced Well-differentiated Neuroendocrine Carcinomas of Non-pancreatic Origin (Carcinoids)”. Protocol Code: AXI-IIG-02. Sponsor: Spanish Neuroendocrine Tumours Group (Grupo Español de Tumores Neuroendocrinos, GETNE). AXI.
  5. “An Observational , Prospective, Multicentre Study to Identify Prognostive and Predictive Biomarkers of Response to Sunitinib in Patients with Well or Moderately Differentiated Pancreatic Islet Cell Tumours and Progressive Metastasis” Protocol Code: SAL-SUN-2011-01. Sponsor: Asociación para el Desarrollo de la Oncología Médica (Association for the Development of Medical Oncology). Hospital Universitario de Salamanca.
  6. “Randomised Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin-Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs) (SEQTOR Study)”. Protocol Code: GETNE-1206. Sponsor: GETNE. SEQTOR.
  7. “A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)”. Protocol Code: GETNE-1407. Sponsor: GETNE. PALBONET.
  8. Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumours (Talent Study). Protocol Code: GETNE-1509. Sponsor: GETNE. TALENT.
  1. A Randomised, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma MK-3475-062.
  2. A Phase III Study of Pembrolizumab vs. Physicians’ Choice of Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Oesophagus that have Progressed after First-Line Standard Therapy. MK-3475-181.
  3. Protocol TO-TAS -102-302 Randomised, Double-Blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC In Patients With Metastatic Gastric Cancer Refractory To Standard Treatments TO-TAS-102-302.
  4. “A Phase 3, Multicentre, Randomised, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma”. Protocol Code: 20070622. Sponsor: Amgen Inc. RILOMET.
  5. “A Randomised, Multicentre, Adaptive Phase II/III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel or Paclitaxel) in Patients With Previously Treated Locally Advanced or Metastatic HER2-positive Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction”. Protocol Code: BO27952. Sponsor: F. Hoffmann-La Roche LTD S.A.GASBY.
  6. “Phase II Study to Assess the Efficacy and Safety of Trastuzumab in Combination With Xelox as First-line Treatment of Patients With Advanced or Metastatic Gastric Cancer with HER2-Positive Tumours”. Protocol Code: FUPOCAN 01-11 (HERXO). Sponsor: Fundación para el Progreso de la Oncología en Cantabria (Foundation for the Progress of Oncology in Cantabria, FUPOCAN). HERXO.
Medullary Thyroid Cancer

“European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib (CAPRELSATM) 300mg in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer”. Protocol Code: D4200C00104. Sponsor: AstraZeneca.

Dr Isabel Palacio Vázquez

  1. “Randomised, Double-Blind, Multicentre, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated with First-Line Chemotherapy, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance” GEICO-1503 / PAOLA-1.
  2. A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. Protocol Code: CO-338-014. Sponsor: Clovis Oncology, Inc. ARIEL.
  3. The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomised, Open-label Phase 3 Study of MEK162 Versus Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum. Protocol Code: ARRAY-162-311. Sponsor: Array- BioPharma INC. MILO.
  4. A Phase 3 Randomised Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer. Protocol Code: PR-30-5011-C. Sponsor: TESARO Inc. NOVA TESARO.
  5. “A Phase 3 Randomised, Double-blind, Placebo-controlled, Multicentre Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers”. Protocol Code: Amgen 20101129/ENGOT-ov2/GOG-3001. Sponsor: Amgen. TRINOVA.
  1. A 3- arm, Phase III, Randomised, Open Label, Multicentre Study of LGX818 plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma. Protocol Code: CMEK162B2301. Sponsor: Novartis. COLUMBUS.
  2. “An Open-Label, Multicentre, Expanded Access Study of RO5185426 in Patients With Metastatic Melanoma”. Protocol Code: MO25515. Sponsor: F. Hoffmann-La Roche LTD.
  3. “A Single-Arm, Open-Label, Multicentre Clinical Trial with Nivolumab for Subjects with Histologically Confirmed Stage III or Stage IV Melanoma Progressing After Prior Treatment Containing an Anti-CTLA-4 Monoclonal Antibody”. Protocol Code: CA209172. Sponsor: Bristol Myers-Squibb Company.

Dr Yolanda Fernández Pérez

  1. A Phase III, Double-Blind, Placebo-Controlled, Randomised Study Of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant In Postmenopausal Women With Oestrogen Receptor-Positive And HER2-Negative Locally Advanced Ormetastatic Breast Cancer Who Have Disease Recurrence Or Progression During Or After Aromatase Inhibitor Therapy. GO29058. SANPPIPER.
  2. A Randomised, Double-blind, Parallel-group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FaslodexTM) 500mg with Placebo and Fulvestrant (FaslodexTM) 500mg in Combination with PD-0332991 (Palbociclib) as First Line Treatment for Postmenopausal Women with Hormone Receptor-positive Metastatic Breast Cancer, Who Have Completed At Least 5 Years of Adjuvant Endocrine Therapy and Remained Disease Free for More Than 12 Months Following its Completion or Have De Novo Metastatic Disease. “The FLIPPER Study” GEICAM/2014-12.
  3. “A One-Cohort , Open-Label, Multicentre Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment”. Protocol Code: MO28231. Sponsor: F. Hoffmann-La Roche LTD. KAMILLA.
  4. “A Phase III Randomised, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment”. Protocol Code: CBKM120F2302. Sponsor: Novartis. BELLE-2.
  5. “A Randomised, Multi-Centre Cross-Over Study to Evaluate Patient Preference and Health Care Professional (HCP) Satisfaction With Subcutaneous (SC) Administration of Trastuzumab in HER2-Positive Early Breast Cancer (EBC)”. Protocol Code: MO22982 Sponsor: F. Hoffmann-La Roche LTD. PREFHER.
  6. “A Phase IIa Prospective, Multicentre, Open and Not Controlled Clinical Trial of the Efficacy and Tolerability of First Line Treatment With Eribulin as a Unic Agent in Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes” Protocol Code: OBU-SW-H-02. Sponsor: Medica Scientia Innovation Research (MedSIR ARO). MERIBEL.
  7. “An Open-label, Multi-centre, Expanded Access Study for Postmenopausal Women with Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who have Progressed Following Prior Endocrine Therapy, Investigating the Treatment of Everolimus (RAD001) in Combination with Exemestane”. Protocol Code: CRAD001YIC04. Sponsor: Novartis. BALLET.
  8. “A Two-cohort, Open-label, Multicentre Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer”. Protocol Code: MO27782. Sponsor: F. Hoffmann-La Roche LTD. VELVET.
  9. “A Randomised Three-Arm, Multicentre Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy”. Protocol Code: BO16348. Sponsor: F. Hoffmann-La Roche LTD. HERA.
  10. Study of Quality of Life in Patients With Metastatic Breast Cancer Treated With Second-line Monochemotherapy. Protocol Code: CEL-CMM-2013-01. Sponsor: Celgene S.L.
  11. A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician’s Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. Protocol Code: D0819C00003. Sponsor: AstraZeneca Farmacéutica Spain, S.A. OLIMPYA.

Dr Noemí Villanueva Palicio

  1. A Randomised, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer. Protocol Code: 20120265. Sponsor: Amgen Inc. MAPLE.
  2. A Randomised, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma. Protocol Code: 9090-14. Sponsor: Synta Pharmaceuticals Corp. GALAXY.
  3. “A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination with the MEK Inhibitor Trametinib in Subjects with BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. Protocol Code: BRF113928. Sponsor: GlaxoSmithKline S.A.
  4. “A Randomised Open-label Phase II Trial of Consolidation With Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy”. Protocol Code: ETOP/IFCT 4-12. Sponsor: European Thoracic Oncology Platform (ETOP). STIMULI.

A Multinational, Phase 3, Randomised, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) 9785-CL-0335.


A Phase 3, Multicentre, Multinational, Randomised, Open-label, Parallel-arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer whose Disease did not Progress After Completion of First-line Platinum-containing Chemotherapy. B9991001 Javelin.


A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy. C31005 Millenium.

Multiple Pathologies

“An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers”. Protocol Code: MO28072. Sponsor: F. Hoffmann-La Roche LTD. VE-BASKET.

Dr María Luque Cabal

  1. A Randomised Multicentre Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Metastatic Breast Cancer (The METRIC Study) CDX011-04.
  2. “Phase II, Randomised, Open-label, Multicentric Clinical Trial of Neoadjuvant Treatment Comprising Chemotherapy and Trastuzumab with or without Metformin, in Women with HER2/ErbB2 Positive Primary Breast Cancer.” Protocol Code: METTEN-01. SPONSOR: Consortium to Support Biomedical Research Networks (Consorcio de Apoyo a la Investigación Biomédica en Red, CAIBER).
  3. “A Randomised, Multicentre, Open-label, Phase II Trial to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With HER2 Negative, ER+ Metastatic Breast Cancer (Parsifal 1)”. Protocol Code: MedOPP067. Sponsor: Medica Scientia Innovation Research (MedSIR ARO). PARSIFAL.